Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for New River Pharmaceuticals Inc. > News item |
Merrill puts New River at buy, raises price target
New River Pharmaceuticals Inc. was rated at a buy with an increased price target of $65 from $47 on a better-than-expected profit share for New River for NRP104, as well as incorporation of the company's pipeline into the valuation. Shares of the Radford, Va.-based pharmaceutical company were up $5.50, or 13.00%, at $47.82. (Nasdaq: NRPH)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.